Non-Fiction Books:

Home  
Books  
Non-Fiction  
Professional & Technical  
Medicine  
Clinical & internal medicine  
Diseases & disorders  
Oncology

Overcoming Cancers Resistant to HER-2 Antibodies

Click to share your rating 0 ratings (0.0/5.0 average) Thanks for your vote!

Format:

Hardback
  • Overcoming Cancers Resistant to HER-2 Antibodies: Volume 3 on Hardback
  • Overcoming Cancers Resistant to HER-2 Antibodies: Volume 3 on Hardback
$251.00
Releases

Pre-order to reserve stock from our first shipment. Your credit card will not be charged until your order is ready to ship.

Available for pre-order now
0 in Trolley
Free Delivery with Primate
Join Now

Free 14 day free trial, cancel anytime.

Buy Now, Pay Later with:

4 payments of $62.75 with Afterpay Learn more

6 weekly interest-free payments of $41.83 with Laybuy Learn more

Pre-order Price Guarantee

If you pre-order an item and the price drops before the release date, you'll pay the lowest price. This happens automatically when you pre-order and pay by credit card or pickup.

If paying by PayPal, Afterpay, Laybuy, Zip, Klarna, POLi, Online EFTPOS or internet banking, and the price drops after you have paid, you can ask for the difference to be refunded.

If Mighty Ape's price changes before release, you'll pay the lowest price.

Availability

This product will be released on

Delivering to:

It should arrive:

  • 7-14 June using International Courier

Explore more Breaking Tolerance to Antibody-mediated Immunotherapy

See all products in this series

T Cell Metabolism and Cancer Immunotherapy on Hardback
$429.00
T Cell Metabolism and Cancer Immunotherapy
Hardback
Pre-order - out 1 Sep 2024

Description

Overcoming Cancers Resistant to HER-2 Antibodies provides general updated information on the resistance of various human cancers to anti-HER2 therapeutic antibodies. The book also discusses the description of various sensitizing agents that can reverse resistance when used in combination with anti-HER2 antibodies. There have been a lot of reports in which the treatment with anti-HER2 antibodies for various cancers has resulted in clinical responses; however, there have been also subsets of cancer patients who did not respond initially, and several responding patients developed resistance following treatments. Sections cover Lapatinib, Ganetespib, Paclitaxel, Celecoxib, Emantasine, Liposomal Doxorubicin, and Kinase Inhibitors. This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of the biomedical field interested in fighting cancer resistance to HER-2 antibodies.

Author Biography:

Dr Bonavida has vast expertise and various reported publications in the field of tumor cell sensitization to chemotherapy (a total of greater than 500 publications) and the novel role of Nitric Oxide (NO) donors in chemo-sensitization and reversal of drug resistance. In addition, he was the first scientist to co-organize an international meeting on the topic (First International Workshop on NO and Cancer, 2005).
Release date NZ
June 1st, 2024
Audience
  • Professional & Vocational
Contributor
  • Edited by Benjamin Bonavida
Pages
250
ISBN-13
9780128164082
Product ID
30461298

Customer previews

Nobody has previewed this product yet. You could be the first!

Write a Preview

Recommended for you

Recommended from your browsing history

Help & options

Filed under...

Books >
Non-Fiction >
Professional & Technical >
Medicine >
Clinical & internal medicine >
Diseases & disorders >
Oncology
Books >
Non-Fiction >
Professional & Technical >
Medicine >
Medicine: general issues >
Public health & preventive medicine >
Personal & public health
Books >
Non-Fiction >
Professional & Technical >
Medicine >
Pre-clinical medicine: basic sciences
Books >
Non-Fiction >
Technology >
Biochemical engineering >
Biotechnology
Books >
Business & Economics >
Industry Studies >
Manufacturing industries >
Hi-tech manufacturing industries >
Biotechnology industries